934 related articles for article (PubMed ID: 24989141)
21. Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S10-9. PubMed ID: 20824235
[TBL] [Abstract][Full Text] [Related]
22. Combination pharmacotherapy with incretins: what works best and when?
Over RK; Ratner RE
Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584
[TBL] [Abstract][Full Text] [Related]
23. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
[TBL] [Abstract][Full Text] [Related]
24. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
25. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
Gautier JF; Choukem SP; Girard J
Diabetes Metab; 2008 Feb; 34 Suppl 2():S65-72. PubMed ID: 18640588
[TBL] [Abstract][Full Text] [Related]
26. Incretin-based therapies in type 2 diabetes mellitus.
Chia CW; Egan JM
J Clin Endocrinol Metab; 2008 Oct; 93(10):3703-16. PubMed ID: 18628530
[TBL] [Abstract][Full Text] [Related]
27. New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy.
Namba M; Katsuno T; Kusunoki Y; Matsuo T; Miuchi M; Miyagawa J
Clin Exp Nephrol; 2013 Feb; 17(1):10-5. PubMed ID: 23135865
[TBL] [Abstract][Full Text] [Related]
28. Incretin physiology and its role in type 2 diabetes mellitus.
Svec F
J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of incretin based therapies: clinical trial data.
White J
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S30-40. PubMed ID: 19801363
[TBL] [Abstract][Full Text] [Related]
30. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.
Stonehouse A; Okerson T; Kendall D; Maggs D
Curr Diabetes Rev; 2008 May; 4(2):101-9. PubMed ID: 18473757
[TBL] [Abstract][Full Text] [Related]
31. Incretin-based therapy of type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Holst JJ
Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
[TBL] [Abstract][Full Text] [Related]
32. Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
Seino Y; Kuwata H; Yabe D
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):102-9. PubMed ID: 27186364
[TBL] [Abstract][Full Text] [Related]
33. Is there a place for incretin therapies in obesity and prediabetes?
Holst JJ; Deacon CF
Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
[TBL] [Abstract][Full Text] [Related]
34. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
Meece J
Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
[TBL] [Abstract][Full Text] [Related]
36. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.
Nauck MA; Meier JJ
Lancet Diabetes Endocrinol; 2016 Jun; 4(6):525-36. PubMed ID: 26876794
[TBL] [Abstract][Full Text] [Related]
37. [The value of incretin based therapies].
Gallwitz B
Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
[No Abstract] [Full Text] [Related]
38. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
39. Incretin effect: GLP-1, GIP, DPP4.
Kazafeos K
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
[TBL] [Abstract][Full Text] [Related]
40. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
